首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Overcoming P-Glycoprotein-Mediated Multidrug Resistance in Colorectal Cancer: Potential Reversal Agents among Herbal Medicines
【24h】

Overcoming P-Glycoprotein-Mediated Multidrug Resistance in Colorectal Cancer: Potential Reversal Agents among Herbal Medicines

机译:在大肠癌中克服P-糖蛋白介导的多药耐药性:中草药之间的潜在逆转剂

获取原文
       

摘要

Objectives. Multidrug resistance (MDR) is the major reason for the failure of chemotherapy in colorectal cancer (CRC), and the primary determinant of MDR in CRC patients is active drug efflux owing to overexpression of P-glycoprotein (P-gp) in cancer tissues. Despite research efforts to overcome P-gp-mediated drug efflux, the high toxicity of P-gp inhibitors has been a major obstacle for the clinical use of these agents. The aim of this study was to review the literature for potential P-gp reversal agents among traditional herbal medicines, which offer the advantages of safety and potential synergetic effects in CRC chemotherapy. Methods. We searched ten databases including 3 English databases, 1 Chinese medical database, and 6 Korean medical databases up to July 2018 and included in vivo and in vitro studies evaluating the effects of herbal medicines as P-gp reversal agents in CRC. Results. A total of 28 potentially related studies were identified and 16 articles were included. Involving 3 studies about Salvia miltiorrhiza and 2 studies about Curcuma longa, finally we found 14 kinds of traditional herbal medicines—Salvia miltiorrhiza, Curcuma longa, Sinomenium acutum, Stephania tetrandra, Bufo gargarizans, Coptis japonica, Piper nigrum and Piper longum, Hedyotis diffusa, Schisandra chinensis, Glycyrrhiza glabra, Glycyrrhiza inflate, Daphne genkwa, Stemona tuberosa Lour, and Andrographis paniculata—as showing efficacy as P-gp inhibitors in anticancer drug-resistant CRC cells in vitro and in vivo. Conclusions. This brief account provides insight into the relationship between P-gp and CRC. Further studies on herbal medicines with demonstrated effects against P-gp overexpression will aid in improving the efficacy of chemotherapy in CRC.
机译:目标。多药耐药性(MDR)是结直肠癌(CRC)化疗失败的主要原因,并且由于癌症组织中P-糖蛋白(P-gp)的过表达,CRC患者MDR的主要决定因素是活性药物外流。尽管人们为克服P-gp介导的药物外流进行了研究,但P-gp抑制剂的高毒性一直是这些药物临床使用的主要障碍。这项研究的目的是回顾传统草药中潜在的P-gp逆转剂的文献,这些文献在CRC化疗中提供安全性和潜在的协同作用。方法。截至2018年7月,我们检索了10个数据库,包括3个英文数据库,1个中医数据库和6个韩国医学数据库,并进行了体内和体外研究,评估了草药作为CRC中P-gp逆转剂的作用。结果。总共确定了28项潜在相关研究,其中包括16篇文章。涉及3个有关丹参的研究和2个关于姜黄的研究,最终我们找到了14种传统草药-丹参,姜黄,中药草,Stephania tenndra,中华大蟾蜍,黄连,日本胡椒,黑胡椒和胡椒,白花蛇舌草,五味子,甘草,甘草膨胀,Daphne genkwa,块茎Stemona tuberosa Lour和穿心莲(Andrographis paniculata)在体外和体内显示出作为P-gp抑制剂在抗癌耐药CRC细胞中的功效。结论。这个简短的介绍可以深入了解P-gp与CRC之间的关系。已证明对P-gp过表达具有影响的草药的进一步研究将有助于改善CRC化疗的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号